Olomoucine

Key Product Details

Product Description

ATP-competitive cyclin-dependent kinase (cdk) inhibitor (reported IC₅₀ values are 0.6 and 0.94 - 8 μM for cdk7 and cdk2 respectively, and >1 μM for cdk1 and cdk9. Induces cell cycle arrest at G1 in human fibroblasts.

Product Specifications for Olomoucine

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for Olomoucine

The following data is based on the product molecular weight 298.35.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.5 mM	6.70 mL	33.52 mL	67.04 mL
2.5 mM	1.34 mL	6.70 mL	13.41 mL
5 mM	0.67 mL	3.35 mL	6.70 mL
25 mM	0.13 mL	0.67 mL	1.34 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 10 publications citing the usage of this product.

• Jorda How selective are pharmacological inhibitors of cell-cycle-regulating cyclin-dependent kinases? J.Med.Chem. 2018 PMID: 30234987
• Alessi The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity. Exp.Cell.Res. 1998 PMID: 9828096
• Vesely Inhibition of cyclin-dependent kinases by purine analogues. Eur.J.Biochem. 1994 PMID: 7925396
• Abraham Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases. Biol.Cell 1995 PMID: 7549905

Product Documents for Olomoucine